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Introduction   
 
General practitioners, geriatricians, neurolo-
gists and health care professionals all over the 
world will be facing by 2040 the diagnostic, 
therapeutic and socioeconomic challenges of 
over 80 million people with dementia, 70% of 
which will be residing in the least developed 
world countries. There are currently 18 million 
people with dementia in Europe, Africa, Asia 
and Latin America, and nearly 29 million de-
mented subject are predicted by 2020 [1-3]. 
There is, however, a striking possibility of un-
derestimation, not only in developing countries, 
due to  inadequate diagnosis, lack of aware-
ness and low education [4].  
 
Dementia is one of the most common diseases 
in the elderly, with crude prevalence rates be-
tween 5.9-9.4% for subjects aged over 65 in 
the European Union [5]. The lowest age- and 
gender-specific prevalence of all-causes de-
mentia reported in the literature is 61.1% 
among women aged 100 or greater [6-8]. De-
mentia drastically affects daily life and every-
day personal activities. It is often associated 
with behavioural symptoms, personality change 
and numerous clinical complications, it in-
creases the risk for urinary incontinence, hip 
fracture, and – most markedly – increases the 
dependence on nursing care. The costs of care 
for patients with dementia are therefore im-
mense [9]. 
 
This review will focus on specific aspects of de-
mentia prevention. Prevention appears to be 
particularly prominent among anti-dementia 
strategies because of the lack of cure for de-
mentia [10] and because it can be carried out 
within a multidimensional scheme with the high-
est chances of success if adopted in the early 
adulthood.  
 
Primary prevention is directed against dementia 
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prior to its biological onset or against demen-
tia’s risk factors, while secondary prevention 
refers to the early detection of asymptomatic 
disease with associated opportunities for inter-
vention before symptoms are evident. However, 
the US Preventive Services Task Force suggests 
there is insufficient evidence to support institut-
ing a universal dementia screening programme 
[11]. Syndromes of cognitive impairment in non-
demented older adults have been the focus of 
studies aiming to identify subjects at high risk to 
develop dementia. Mild cognitive impairment 
(MCI) is characterized by isolated memory defi-
cits in non-demented persons with subjective 
memory problems, normal general cognitive 
functioning, and intact activities of daily living 
[12]. In the attempt of avoiding dementia devel-
opment, there are several risk factors to be 
taken into account, some of which are non-
modifiable and include age with age-influencing 
early-life deleterious conditions [13], gender, 
and genetic influence [14]. In addition, there 
are several inborn physical attributes, factors 
such as illiteracy and lack of early education, 
environmental stress, as well as accidents and 
traumas that have been associated with in-
creased risk for dementia [13,15].  
 
A great deal of attention is being dedicated to 
the identification and modulation of those fac-
tors which have a large potential to be managed 
before the onset or during the early asympto-
matic course of the disease. These include vas-
cular and lifestyle factors. Among vascular risk 
factors, considerable evidence from randomized 
controlled trials and longitudinal cohort studies 
has established the relationship between hyper-
tension and dementia as well as between hyper-
lipidemia and dementia. Both systolic hyperten-
sion above 160 mmHg and serum cholesterol 
above 6.5 mmol/L are known to be associated 
with an increased RR of 1.5 and 2.1 to develop 
AD [reviewed in 15]. Based on the recommen-
dations of the Third Canadian Consensus Con-
ference on Diagnosis and Treatment of Demen-
tia held in March 2006 [15], statin therapy, ace-
tylsalicylic acid and carotid artery stenosis re-
opening on a first level of evidence and control 
of type 2 diabetes mellitus, hyperlipidemia and 
hyperhomocysteinemia on a second level of 
evidence should not be recommended with the 
single specific purpose of reducing the risk of 
dementia. Similarly, a recent Cochrane review 
concluded that there was insufficient evidence 
to suggest the use of statins for the prevention 
of AD based on two prospective randomised, 
placebo-controlled studies (RCTs); the Heart 
Protection Study and the PROSPER study. Both 
studies examined the effects of statins in sub-
jects aged over 70 years of age. However, these 
RCTs do not address the primary epidemiologi-
cal observations and nested case-control stud-
ies, that reduction of serum cholesterol in mid-
life offers benefit [16, 17]. 
 
The aim of this work is to critically discuss some 
of the main results reported recently in the lit-
erature in this respect and to provide the patho-
physiological rationale for the control of dyslipi-
demia in the prevention of dementia onset and 
progression. 
 
Cholesterol metabolism in the brain 
 
In the central nervous system, cholesterol is 
unesterified and resides in the myelin sheaths 
(oligodendroglia) and in the plasma membranes 
of astrocytes and neurons. Up to 70% of brain 
cholesterol is myelin-associated. As half of the 
brain’s white matter is composed of myelin, the 
brain is the most cholesterol-rich organ in the 
body. Cholesterol plays an essential role in 
membrane organization and function as it in-
duces large changes in membrane fluidity. The 
bulk of brain cholesterol in the adult human 
brain has a half-life of at least five years, show-
ing the efficiency of cholesterol reutilization 
which is achieved via the cholesterol 24-
hydroxylase enzyme that is expressed in neu-
rones particularly in the hippocanpus and cortex 
where it is considered important for memory 
and learning [18].The current consensus is that 
cholesterol in the brain is insulated from 
changes in circulating cholesterol. The blood-
brain barrier prevents diffusion of large mole-
cules at the level of tight junctional attachments 
between adjacent capillary endothelial cells; 
however, brain endothelial cells have the poten-
tial to take-up low-density lipoprotein choles-
terol through luminal LDL receptors that recog-
nize apolipoprotein E (apoE) and translocate 
LDL across the cell (reviewed in [15]).  
 
ApoE, cholesterol and dementias 
 
ApoE is one of the major apolipoproteins in 
plasma and quantitatively the most important 
transport protein for cholesterol in the brain. It 
is mainly synthesized by the astrocytes [19], 
although microglia and neurons are also able to 
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synthesize some apoE under specific conditions 
[20], One of the 3 human isoforms of apoE, 
apoE4, is a well-documented risk factor for Alz-
heimer’s disease (AD) (reviewed in [21]). The 
discovery that apoE4 alleles and certain genetic 
variants of IL-1 are linked to dementia support 
the involvement of both inflammation and dys-
regulation of lipid metabolism in the develop-
ment of dementia [22,23].  
 
ApoE plays a crucial role in lipid transport in the 
blood, brain, and cerebrospinal fluid in health 
and disease. There are important associations 
between dietary factors and apoE polymor-
phisms, which give us a clue to consider dietary 
fat patterns in the population. Recently, a num-
ber of dietary elements and foods have been 
reported to be either risk or protective factors 
for the development of dementia and AD. These 
include fat, fatty acids, antioxidants, fish, homo-
cysteine/methionine, vitamins and alcohol [24].  
 
The relationship between β-amyloid (Aβ) and 
cholesterol was first investigated in cultured 
cells [25] and later work in a transgenic mouse 
model of AD amyloidosis which demonstrated 
that diet-induced hypercholesterolemia resulted 
in a dramatic acceleration of the neuropa-
thological and biochemical changes in the trans-
genic mice [26]. These initial studies also 
showed the correlation between levels of total 
Aβ and both plasma and CNS total cholesterol 
as well as the relationship between cholesterol 
levels and Aβ cleavage [27] and were confirmed 
by in vitro observations of a decreased rate of 
Aβ secretion in cells depleted of cholesterol 
[28].  
 
Several clinical studies have identified the asso-
ciation, in humans, between total plasma cho-
lesterol and AD risk. After controlling for age 
and apoE isoforms, previous and midlife high 
plasma cholesterol levels are a consistent pre-
dictor of AD and MCI. In some reports, in-
creased levels of midlife total cholesterol are 
associated with two- and threefold increase in 
the risk to develop dementia and AD in later life 
[29-32]. In addition, low HDL-cholesterol are 
associated with elevated risk for dementia and 
high levels of HDL cholesterol are associated 
with larger hippocampal volume and protection 
against dementia and AD [33]. Hypercholes-
terolemia in midlife may lead to enhanced cho-
lesterol membrane content, and a correspond-
ing increase in the surface area of lipid rafts 
that can potentiate the activity of b-secretase 
and therefore Aβ production. Statins, the most 
prescribed lipid-altering drugs, are used to suc-
cessfully decrease vascular death, myocardial 
infarction, stroke and in general to prevent car-
diovascular diseases that are correlated with 
AD. In light of the hypothesis that the competi-
tive inhibitors of HMG-CoA reductase could have 
beneficial effects on AD, the efficacy of statin 
treatment has been studied in AD. This treat-
ment has been in fact found to be associated 
with reduced prevalence for probable AD by up 
to 73%, reduce Aβ production by 50%, reduce 
plaque formation [34-36] and cholesterol CSF 
levels [37]. In this respect, modulation of cho-
lesterol in midlife appears to afford cognitive 
advantage during ageing, despite the fact that 
some of the statins studied do not cross the 
blood brain barrier. One potential mechanism by 
which a reduction in peripheral serum choles-
terol may be effective in reducing AD incidence 
is through a reduction in oxidative stress, as the 
longer LDL circulation time observed in patients 
with hypercholesterolaemia gives rise to ele-
vated levels of oxidized lipids that are in them-
selves lipophilic and cytotoxic oxidative stress-
ors.    
 
Oxidative stress and the AD brain 
 
Evidence that AD brain is subject to a critical 
oxidative stress load and that an initial source 
of oxidative stress such as high cholesterol may 
initiate amyloid formation is increasing. Lipid 
peroxidation is the mechanism by which lipids 
are attacked by free radicals. The latter must 
have sufficient reactivity to abstract a hydrogen 
atom from a methylene carbon in their side 
chain. The greater the number of double bonds 
in the molecule, the higher the chance that the 
hydrogen atom is removed. Polyunsaturated 
fatty acids, in fact, are particularly susceptible 
to lipid peroxidation. Brain membrane phosphol-
ipids are composed by PUFAs, primarily arachi-
donic and docosahexaenoic acid. Oxidation of 
these acids produced aldehydes, such as 
malondialdehyde and 4-hydroxy-nonenal. In 
addition, F2-isoprostanes are prostaglandin-like 
compounds formed non-enzymatically by free 
radical-induced oxidation of fatty acids. Peroxi-
dation of cellular membranes can, in turn, pro-
pogate free radical chain reactions. Several 
neurotoxic substances of altered lipid metabo-
lism have been found in AD which may involve 
free radical damage and include 24s-
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hydroxycholesterol (the main cholesterol elimi-
nation byproduct of the brain) [38], malondial-
dehyde [39], lipofuscin and several aldehydes 
and F2-isoprostanes (reviewed in [40]).  
 
Significant increases in levels of membrane-
associated oxidative stress, and free cholesterol 
in brain cells during normal aging have been 
detected in mice, in AD patients and in neurons 
exposed to Aβ. This associates with a reduction 
in intracellular glutathione and an altered redox 
balance within the cells that signals activation 
of several transcription factors (e.g. NF-kB) and 
enzymes (acid sphingomyelinase). The latter 
catalyses the release of long chain ceramides 
from membrane sphingolipids and alters the 
structure of the lipid rafts in membranes. As the 
membrane microdomains rich in cholesterol 
and sphingolipids play important roles in vari-
ous signaling pathways, cell proliferation, differ-
entiation and death, the observed reversion of 
ceramide changes in vitro by α-tocopherol 
(probably by conserving the intracellular redox 
state) is not a minor finding [41].  
 
24s-hydroxycholesterol is an oxysterol gener-
ated in the brain by the cytochrome P-450 
(CYP46A1) and can escape the recycling 
mechanism by traversing the blood-brain bar-
rier. The ability for cholesterol transport or recy-
cling in the brain seems to be of importance for 
the development of AD as 24s-
hydroxycholesterol is an effective inhibitor of 
beta amyloid formation [42]. In contrast, the 
systemically oxidized cholesterol product, 27-
hydroxycholesterol, can be transported from the 
periphery across the blood-brain barrier and is 
observed at increased levels in the AD brain 
[43]. Indeed, the increased ratio of 27:24s- hy-
droxycholesterol has been proposed to favour 
the formation of beta amyloid [44].   
 
Epidemiological evidence for a protective role of 
diet against AD development 
 
The foregoing evidence implicates a role for 
dyslipidemia and lipid peroxidation in increasing 
AD risk, possibly through the uptake of systemi-
cally oxidized cholesterol such as 27-
hydoxycholesterol, that can result in neuronal 
toxicity either directly or indirectly via increased 
amyloid beta secretion, GSH oxidation, cera-
mide formation and enhanced cytotoxic signal-
ing. This has prompted the evaluation of protec-
tive dietary patterns against dementia develop-
ment. Among various composite dietary pat-
terns, a large amount of attention has been 
lately dedicated to the Mediterranean Diet 
(MeDi). This is characterized by high intake of 
vegetables, legumes, fruits, cereals, unsatu-
rated fatty acids (mostly in the form of olive oil), 
low intake of saturated fatty acids, moderately 
high intake of fish, and a tendency for low in-
take of dairy products and meat. In the typical 
MeDi, alcohol intake is low to moderate but 
regular, generally during meals. High MeDi ad-
herence is associated with lower AD risk [45, 
46] and furthermore may impact on AD course 
and prognosis, as shown by the observation 
that AD patients in the middle and higher tertile 
of MeDi adherence have lower and lowest mor-
tality risk, respectively compared to AD patients 
in the lowest tertile [47]. After adjusting for age, 
gender, education, marital status, depressive 
symptomatology, taking 5 drugs or more, apoE 
genotype, stroke and cardiovascular risk fac-
tors, a higher MeDi score was recently found to 
be associated with fewer errors at MMSE in a 
prospective cohort study of 1410 elderly sub-
jects [40]. In this study, the performance on 
three further neuropsychological tests was not 
consistently associated with MeDi adherence 
[48]. The authors suggested that the main rea-
son for the discrepancy between the previous 
US studies [45-47] and the latter French one 
[48] might be related to the different population 
studied and the country-specific characteristics 
of the dietary patterns. The association between 
cognitive performance and MeDi, however, ap-
pears to be a strong one and has been recently 
confirmed by the relationship between high ad-
herence to the MeDi and reduced risk for devel-
oping MCI and for converting from MCI to AD 
[49]. Both higher Mediterranean-type diet ad-
herence and higher physical activity were inde-
pendently associated with reduced risk for AD in 
a prospective cohort study of two cohorts com-
prising 1880 community dwellers without de-
mentia living in New York [50]. It might be possi-
ble that the synergistic lipid-lowering and anti-
oxidant activity of specific MeDi food categories 
is able to influence the onset and course of de-
mentia.  
 
A large amount of attention has been dedicated 
in the past decades to the role of oxidative 
stress and altered redox balance in the progres-
sion of aging brain to mild cognitive impairment 
and dementia [51] as well to the protective role 
of antioxidant micronutrients against AD devel-
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opment [52]. Recently, the simultaneous asso-
ciation between antioxidant micronutrient, fruit 
and vegetable intake and cognitive performance 
has been observed in healthy individuals across 
a broad age range, suggesting that at least 
some of the cognitive-enhancing effects of a 
fruit and vegetable-rich diet are mediated by 
oxidative stress-lowering substances [53]. 
These results need to be confirmed in larger 
population studies, as health-conscious sub-
jects further increasing their fruit and vegetable 
intake for a longitudinal period of three months 
do not appear to benefit from a simultaneous 
decrease in systemic oxidative stress bio-
markers [54]. As oxidative LDL modification 
appears to be inversely correlated to cognitive 
performance [55], the impact of dietary modifi-
cations with increased fruit and vegetable in-
take on levels of oxidized molecules that can 
cross the blood-brain barrier e.g.27-
hydroxycholesterol may prove more informative 
for assessing a reduction in risk for AD. 
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